ReviewHuman vaccines & immunotherapeutics2023
Recombinant zoster vaccine in immunocompetent and immunocompromised adults: A review of clinical studies.
Review in Human vaccines & immunotherapeutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 4 syntheses or guidelines pooled it, 32 citations in OpenAlex.
- Janus kinase inhibitors in the management of lichen planus: a systematic review.Annals of medicine · 2026Pooled it
- Effectiveness of pharmacist-delivered vaccination recommendations for herpes zoster: a systematic review.Frontiers in public health · 2026Pooled it
- Immunogenicity and safety of live attenuated and recombinant/inactivated varicella zoster vaccines in people living with HIV: A systematic review.Human vaccines & immunotherapeutics · 2024Pooled it
- Differential Utility Losses in Herpes Zoster Cases Between Vaccinated and Unvaccinated Subjects: A Meta-analysis of Three Clinical Trials.Clinical drug investigation · 2024Pooled it
- Trial
- Quantitative study of the knowledge, attitudes, and practices (KAP) towards herpes zoster (HZ) and HZ vaccination: Survey findings from a multi-country study in Asia (ZOASIS).Human vaccines & immunotherapeutics · 2026Article
- The epidemiological impact and effectiveness of herpes zoster vaccination among older and pharmacologically immunocompromised adults: a population-based observational study.The Lancet regional health. Western Pacific · 2026Article
- Cost Effectiveness of the Adjuvanted Recombinant Zoster Vaccine in Older Adults in Portugal.PharmacoEconomics - open · 2026Article
- Review
- Informing decisions in light of parameter uncertainty - an economic evaluation of the adjuvanted recombinant herpes zoster vaccine in Sweden.The European journal of health economics : HEPAC : health economics in prevention and care · 2026Article
- Repeated dose toxicity and immunogenicity studies in SD rats: a new recombinant zoster vaccine (CHO cell) formulated with adjuvant BC02.Frontiers in cellular and infection microbiology · 2026Article
- Effectiveness of Recombinant Herpes Zoster Vaccine in the U.S. Medicare Population, 2018 to 2019, by Immunocompetence and Prior Receipt of Live Zoster Vaccine.Annals of internal medicine · 2025Article
- Off-label use of recombinant adjuvanted Herpes Zoster vaccine in a 10-year-old high-risk patient affected by epidermolysis bullosa: A case report.Human vaccines & immunotherapeutics · 2025Article
- Article
- Genetic Evidence Indicates that Serum Micronutrient Levels Mediate the Causal Relationships Between Immune Cells and Neuropathic Pain: A Mediation Mendelian Randomization Study.Molecular neurobiology · 2025Article
- Detection of Varicella Zoster Virus Reactivation in Cerebrospinal Fluid in Ischemic Stroke or Transient Ischemic Attack.Journal of the American Heart Association · 2025Article
- Real-world data on the use of the Shingrix vaccine among patients with inflammatory arthritis and risk of cardiovascular events following herpes zoster.Arthritis research & therapy · 2025Observational
- Varicella and Zoster Vaccination Strategies in Immunosuppressed Pediatric Transplant Recipients.Vaccines · 2025Review
- Article
- Herpes Zoster Risk Among US Cancer Patients Following Initiation of Immunosuppressive Therapy.Cancer management and research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Herpes zoster (HZ) is a debilitating vaccine-preventable disease. Impairment of cell-mediated immunity, as observed with aging and immunosuppressive disorders and therapies, increases risk. Recombinant zoster vaccine (RZV) is efficacious against HZ in adults aged ≥50 years in different settings, and in immunocompromised adults aged ≥18 years who are at increased risk of developing HZ. RZV is the first and only HZ vaccine approved for use in immunocompromised adults globally, including in Europe and the US. RZV has a clinically acceptable safety profile and elicits robust immune responses in adults aged ≥50 years, and in immunocompromised adults aged ≥18 years who are at increased risk of HZ. Additionally, RZV is efficacious against HZ complications such as post-herpetic neuralgia and HZ-related pain. This review updates knowledge from a randomized controlled trial setting on the efficacy, safety, immunogenicity, and impact on quality of life of RZV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.